Archivio istituzionale della ricerca dell'Università degli Studi di Palermo

CABIBBO, Giuseppe
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 10.933
EU - Europa 6.403
AS - Asia 5.971
SA - Sud America 1.000
AF - Africa 199
OC - Oceania 16
Continente sconosciuto - Info sul continente non disponibili 7
AN - Antartide 1
Totale 24.530
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 10.750
SG - Singapore 2.225
RU - Federazione Russa 1.924
CN - Cina 1.470
IT - Italia 1.379
BR - Brasile 785
HK - Hong Kong 664
DE - Germania 598
VN - Vietnam 588
FI - Finlandia 569
PL - Polonia 450
FR - Francia 305
GB - Regno Unito 276
UA - Ucraina 276
JP - Giappone 193
IE - Irlanda 187
BD - Bangladesh 184
IN - India 132
KR - Corea 117
CA - Canada 97
SE - Svezia 86
NL - Olanda 79
AR - Argentina 78
CI - Costa d'Avorio 62
RO - Romania 57
IQ - Iraq 56
TR - Turchia 52
MX - Messico 51
AT - Austria 45
ES - Italia 44
ZA - Sudafrica 38
BE - Belgio 35
EC - Ecuador 33
ID - Indonesia 33
SA - Arabia Saudita 28
PK - Pakistan 27
CO - Colombia 25
UZ - Uzbekistan 25
PY - Paraguay 24
PH - Filippine 22
MA - Marocco 21
EG - Egitto 20
KE - Kenya 20
MY - Malesia 18
VE - Venezuela 18
CH - Svizzera 14
IR - Iran 14
LT - Lituania 14
AU - Australia 13
AZ - Azerbaigian 13
JO - Giordania 13
PE - Perù 11
TN - Tunisia 11
BO - Bolivia 10
KZ - Kazakistan 10
AE - Emirati Arabi Uniti 9
CL - Cile 9
IL - Israele 9
NP - Nepal 9
PS - Palestinian Territory 9
DZ - Algeria 8
JM - Giamaica 8
LB - Libano 8
TW - Taiwan 8
BG - Bulgaria 7
DK - Danimarca 7
OM - Oman 7
TH - Thailandia 7
AL - Albania 6
CZ - Repubblica Ceca 6
MD - Moldavia 6
PA - Panama 6
RS - Serbia 6
SN - Senegal 6
BY - Bielorussia 5
GE - Georgia 5
NI - Nicaragua 5
UY - Uruguay 5
AO - Angola 4
BH - Bahrain 4
CR - Costa Rica 4
DO - Repubblica Dominicana 4
EU - Europa 4
GR - Grecia 4
LV - Lettonia 4
KG - Kirghizistan 3
NZ - Nuova Zelanda 3
PT - Portogallo 3
XK - ???statistics.table.value.countryCode.XK??? 3
AF - Afghanistan, Repubblica islamica di 2
BA - Bosnia-Erzegovina 2
EE - Estonia 2
GT - Guatemala 2
HU - Ungheria 2
SY - Repubblica araba siriana 2
TG - Togo 2
TT - Trinidad e Tobago 2
AQ - Antartide 1
BN - Brunei Darussalam 1
BW - Botswana 1
Totale 24.509
Salva come PNG Salva come JPEG
Città #
Singapore 1.497
Ashburn 1.433
Fairfield 1.136
San Jose 760
Chandler 723
Hong Kong 640
Woodbridge 556
Houston 448
Seattle 428
Wilmington 406
Zgierz 385
Cambridge 378
Moscow 333
Ann Arbor 304
Palermo 236
Council Bluffs 230
Beijing 224
New York 213
Ho Chi Minh City 207
Los Angeles 193
Medford 191
Dublin 186
Tokyo 186
Lauterbourg 178
Helsinki 162
Altamura 161
Santa Clara 156
Hanoi 155
Dallas 140
Jacksonville 137
Hefei 131
Princeton 116
Frankfurt am Main 114
Lawrence 109
Nanjing 101
Des Moines 88
Buffalo 82
São Paulo 81
Milan 78
The Dalles 78
Rome 70
San Diego 67
London 64
Abidjan 62
Jinan 58
Orem 57
Boardman 53
Chicago 49
Lappeenranta 49
Nuremberg 49
Phoenix 46
Warsaw 46
Dearborn 45
Venice 45
Ludwigshafen am Rhein 44
Shenyang 44
Tulsa 38
Montreal 37
Changsha 35
Atlanta 34
Brussels 34
Columbus 34
Hebei 33
Denver 32
Haiphong 32
Tianjin 32
Nanchang 31
Zhengzhou 31
Brooklyn 30
Da Nang 28
Poplar 28
Chennai 27
Amsterdam 25
Baghdad 24
Paris 24
Munich 23
Ningbo 23
Guangzhou 22
Hangzhou 22
Johannesburg 22
Toronto 22
Tashkent 21
Bremen 20
Kumar 20
Rio de Janeiro 20
Saint Petersburg 20
Vienna 20
Jiaxing 19
Turin 19
Curitiba 18
Pune 18
Shanghai 18
Redondo Beach 17
Ankara 16
Bupyeong-gu 16
Nairobi 16
Verona 16
Krefeld 15
Mexico City 15
Stockholm 15
Totale 15.270
Salva come PNG Salva come JPEG
Nome #
A meta-analysis of survival rates of untreated patients in randomized clinical trials of hepatocellular carcinoma. 325
Effects of Eradicating Hepatitis C Virus Infection in Patients With Cirrhosis Differ With Stage of Portal Hypertension 284
Survival of Patients with Hepatocellular Carcinoma (HCC) Treated by Percutaneous Radio-Frequency Ablation (RFA) Is Affected by Complete Radiological Response 273
Causes of and prevention strategies for hepatocellular carcinoma. 265
A meta-analysis of single HCV-untreated arm of studies evaluating outcomes after curative treatments of HCV-related hepatocellular carcinoma 262
The cheating liver: imaging of focal steatosis and fatty sparing 249
Body Mass Index and Liver Stiffness Affect Accuracy of Ultrasonography in Detecting Steatosis in Patients With Chronic Hepatitis C Virus Genotype 1 Infection 248
Steatosis affects the performance of liver stiffness measurement for fibrosis assessment in patients with genotype 1 chronic hepatitis C 244
Direct acting antivirals after successful treatment of early hepatocellular carcinoma improve survival in HCV-cirrhotic patients 244
Computed tomography of bowel obstruction: Tricks of the trade 239
Assessment of treatment response in hepatocellular carcinoma: a review of literature 236
Treatment of hepatocellular carcinoma: present and future. 234
Predicting survival in patients with hepatocellular carcinoma treated by transarterial chemoembolisation 233
Focal lesions in cirrhotic liver: what else beyond hepatocellular carcinoma? 231
Survival of patients with hepatocellular carcinoma in cirrhosis: a comparison of BCLC, CLIP and GRETCH staging systems 230
Hepatocellular carcinoma recurrence in patients with curative resection or ablation: impact of HCV eradication does not depend on the use of interferon 229
L'impiego del Tachosil in chirurgia epatica 227
Seeding after radiofrequency ablation of hepatocellular carcinoma in patients with cirrhosis: a prospective study. 222
Imaging findings of liver resection using a bipolar radiofrequency electrosurgical device-Initial observations. 221
Treatment of hepatocellular carcinoma in compensated cirrhosis with radio-frequency thermal ablation (RFTA): a prospective study 218
Cost-effectiveness of boceprevir or telaprevir for previously treated patients with genotype 1 chronic hepatitis C 217
The impact of radiotherapy on survival in resectable gastric carcinoma: A meta-analysis of literature data. 213
Hepatocellular carcinoma and synchronous liver metastases from colorectal cancer in cirrhosis: A case report. 212
Disease outcomes after DAA-induced SVR: Data from the resist-HCV cohort 211
Minor hepatic resection using heat coagulative necrosis. 207
Magnetic resonance imaging of the cirrhotic liver in the era of gadoxetic acid 207
Cost analysis of recall strategies for non-invasive diagnosis of small hepatocellular carcinoma 204
"Should cirrhosis change our attitude towards treating non-hepatic cancer?" 204
Meta-analysis of the placebo rates of clinical relapse and severe endoscopic recurrence in post-operative Crohn's disease 203
Optimizing sequential systemic therapies for advanced hepatocellular carcinoma: A decision analysis 202
Update on new approaches in the management of hepatocellular carcinoma. 201
Cost-effectiveness of sofosbuvir-based triple therapy for untreated patients with genotype 1 chronic hepatitis C 200
Natural history of untreatable hepatocellular carcinoma: A retrospective cohort study 199
Primary biliary cirrhosis and hereditary hemorrhagic telangiectasia: When two rare diseases coexist 196
Direct-acting antivirals after successful treatment of early hepatocellular carcinoma improve survival in HCV-cirrhotic patients 193
Risk Factors for Rate of Relapse and Effects of Steroid Maintenance Therapy in Patients With Autoimmune Pancreatitis: Systematic Review and Meta-analysis 193
Hepatic decompensation is the major driver of death in HCV-infected cirrhotic patients with successfully treated early hepatocellular carcinoma 193
Retreatment with pegylated interferon plus ribavirin of chronic hepatitis C non-responders to interferon plus ribavirin: A meta-analysis. 189
Predictors of survival in patients with advanced hepatocellular carcinoma who permanently discontinued sorafenib 188
Progression-Free Survival Early Assessment Is a Robust Surrogate Endpoint of Overall Survival in Immunotherapy Trials of Hepatocellular Carcinoma 188
Mortality in patients with hepatocellular carcinoma predicted by six scoring: none is the winner 187
Radio-frequency thermal ablation (RFTA) of small hepatocellular carcinoma in patients with cirrhosis. Experience at a single tertiary referral center 187
Field-practice study of sorafenib therapy for hepatocellular carcinoma: a prospective multicenter study in Italy. 186
Improved survival of patients with hepatocellular carcinoma and compensated hepatitis C virus-related cirrhosis who attained sustained virological response 183
Sicurezza ed efficacia della chemioembolizzazione arteriosa transcatetere nel trattamento dei pazienti con epatocarcinoma: studio triennale di 75 pazienti italiani 181
Treatment of hepatitis C: critical appraisal of the evidence 180
Cost-effectiveness of sorafenib treatment in field practice for patients with hepatocellular carcinoma. 179
Management of cirrhotic patients with hepatocellular carcinoma treated with sorafenib. 178
A rs4374383 Single Nucleotide Polymorphisms of MERTK gene is linked to a higher likelihood of hepatocellular carcinoma in patients with HCV cirrhosis 178
Antiviral therapy in the palliative setting of HCC (BCLC-B and -C) 177
Letter: liver dysfunction and survival in hepatocellular carcinoma treated by transarterial chemoembolisation - authors' reply 175
Imaging appearance of treated hepatocellular carcinoma. 174
The changing scenario of hepatocellular carcinoma in Italy: an update 174
Hepatocellular carcinoma enhancement on contrast-enhanced CT and MR imaging: response assessment after treatment with sorafenib: preliminary results. 173
Direct antiviral agents and risk for HCC early recurrence: Much ado about nothing 172
Are radiological endpoints surrogate outcomes of overall survival in hepatocellular carcinoma treated with transarterial chemoembolization? 172
Neoangiogenesis-related genes are hallmarks of fast-growing hepatocellular carcinomas and worst survival. results from a prospective study 171
Hepatocellular Cancer: Optimal Strategies for Screening and Surveillance 170
Is early recurrence of hepatocellular carcinoma in HCV cirrhotic patients affected by treatment with direct-acting antivirals? A prospective multicentre study 170
L'impiego del Tissue-Link FB3.0 floating ball nelle resezioni epatiche 169
Gadoxetic acid-enhanced MRI of transient hepatic enhancement differences: Another cause of hypointense observation on hepatobiliary phase 167
Hyperferritinemia is a risk factor for steatosis in chronic liver disease. 166
Long-Term Course of Chronic Hepatitis C in Children: From Viral Clearance to End-Stage Liver Disease 165
Sorafenib for hepatocellular carcinoma: From randomized controlled trials to clinical practice 164
Systemic therapies for hepatocellular carcinoma: The present and the future 164
Rise and fall of HCV-related hepatocellular carcinoma in Italy: a long-term survey from the ITA.LI.CA centres. 158
NT pro BNP plasma level and atrial volume are linked to the severity of liver cirrhosis. 157
Hepatic decompensation is the major driver of mortality in patients with HCC treated with atezolizumab plus bevacizumab: The impact of successful antiviral treatment 156
Prognostic scores for hepatocellular carcinoma: none is the winner. 155
Extrahepatic spread of hepatocellular carcinoma 154
Multimodal approaches to the treatment of hepatocellular carcinoma. 153
Material deprivation affects the management and clinical outcome of hepatocellular carcinoma in a high-resource environment 152
Direct-acting antiviral agents and risk of Hepatocellular carcinoma: Critical appraisal of the evidence 152
Balancing Efficacy and Tolerability of First-Line Systemic Therapies for Advanced Hepatocellular Carcinoma: A Network Meta-Analysis 150
Personalized cost-effectiveness of boceprevir-based triple therapy for untreated patients with genotype 1 chronic hepatitis C 150
Survival of patients with HCV cirrhosis and sustained virologic response is similar to the general population. 147
Epidemiological trends and trajectories of MAFLD-associated hepatocellular carcinoma 2002-2033: the ITA.LI.CA database 143
Atezolizumab plus bevacizumab versus lenvatinib or sorafenib in non-viral unresectable hepatocellular carcinoma: an international propensity score matching analysis 141
Seeding after radiofrequency thermal ablation of hepatocellular carcinoma in cirrhosis: a prospective study 141
The Evolving Scenario in the Assessment of Radiological Response for Hepatocellular Carcinoma in the Era of Immunotherapy: Strengths and Weaknesses of Surrogate Endpoints 139
Is the efficacy of sorafenib treatment in patients with hepatocellular carcinoma affected by age? 139
Long-term evolution of LI-RADS observations in HCV-related cirrhosis treated with direct-acting antivirals 138
Assessing the impact of COVID-19 on liver cancer management (CERO-19) 137
Heart rate variability is associated with disease severity and portal hypertension in cirrhosis 132
First-Line Immune Checkpoint Inhibitor-Based Sequential Therapies for Advanced Hepatocellular Carcinoma: Rationale for Future Trials 131
Hepatocellular carcinoma recurrence after direct-acting antiviral therapy: An individual patient data meta-analysis 128
RESIST-HCV Criteria to Monitor Progression of Low-Risk Esophageal Varices in Patients With Compensated Cirrhosis After HCV Eradication: The SIMPLE Study: SIMPLE: Scoring Index to Monitor Progression of Low-risk Esophageal varices 127
Epidemiology, risk factors and surveillance of hepatocellular carcinoma 125
Liver and cardiovascular mortality after hepatitis C virus eradication by DAA: Data from RESIST-HCV cohort 125
Hepatocellular carcinoma with macrovascular invasion: Multimodality imaging features for the diagnosis 124
Benign liver lesions 2022: Guideline for clinical practice of Associazione Italiana Studio del Fegato (AISF), Società Italiana di Radiologia Medica e Interventistica (SIRM), Società Italiana di Chirurgia (SIC), Società Italiana di Ultrasonologia in Medicina e Biologia (SIUMB), Associazione Italiana di Chirurgia Epatobilio-Pancreatica (AICEP), Società Italiana Trapianti d'Organo (SITO), Società Italiana di Anatomia Patologica e Citologia Diagnostica (SIAPEC-IAP) - Part I - Cystic lesions 123
Benign liver lesions 2022: Guideline for clinical practice of Associazione Italiana Studio del Fegato (AISF), Società Italiana di Radiologia Medica e Interventistica (SIRM), Società Italiana di Chirurgia (SIC), Società Italiana di Ultrasonologia in Medicina e Biologia (SIUMB), Associazione Italiana di Chirurgia Epatobilio-Pancreatica (AICEP), Società Italiana Trapianti d'Organo (SITO), Società Italiana di Anatomia Patologica e Citologia Diagnostica (SIAPEC-IAP) - Part II - Solid lesions 123
Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial 122
What is the benefit of prophylaxis to prevent HBV reactivation in HBsAg-negative anti-HBc-positive patients? Meta-analysis and decision curve analysis 121
Glucagon-like peptide-1 receptor agonist use is associated with a lower risk of major adverse liver-related outcomes: a meta-analysis of observational cohort studies 121
Direct-acting antiviral agents and risk of hepatocellular carcinoma: is it still a clinical dilemma? 121
Hyperintense nodule-in-nodule on hepatobiliary phase arising within hypovascular hypointense nodule: Outcome and rate of hypervascular transformation 119
Second line systemic therapies for hepatocellular carcinoma: Reasons for the failure 118
Surveillance for hepatocellular carcinoma with a 3-months interval in “extremely high-risk” patients does not further improve survival 118
Contrast ultrasound LI-RADS LR-5 identifies hepatocellular carcinoma in cirrhosis in a multicenter restropective study of 1,006 nodules 116
Totale 18.052
Salva come PNG Salva come JPEG
Categoria #
all - tutte 92.383
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 92.383
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021277 0 0 0 0 0 0 0 0 0 0 140 137
2021/20221.463 107 226 32 36 31 61 57 110 211 134 199 259
2022/20232.251 205 446 39 218 242 297 100 156 373 51 93 31
2023/20241.015 44 140 49 69 71 280 105 60 24 26 42 105
2024/20253.242 85 183 358 283 93 140 200 170 237 342 407 744
2025/202611.457 708 357 780 1.245 1.077 1.717 1.580 1.328 996 1.122 547 0
Totale 25.473